Mycophenolate vs Azathioprine Side Effect Profile
Mycophenolate mofetil is associated with significantly higher rates of gastrointestinal side effects (particularly diarrhea at 14% and GI bleeding requiring hospitalization in 3-5.4% of transplant patients), while azathioprine causes substantially more hepatotoxicity with elevated liver enzymes being the most common side effect (23% liver dysfunction). 1, 2, 3
Key Side Effect Differences
Gastrointestinal Toxicity
Mycophenolate causes more frequent and severe GI complications:
Azathioprine has lower GI toxicity overall, though still present
Hepatotoxicity
Azathioprine demonstrates significantly higher liver toxicity:
Mycophenolate shows minimal hepatotoxicity
Overall Tolerability and Discontinuation Rates
Azathioprine is significantly more likely to be discontinued due to side effects than mycophenolate 2. In real-world data from 235 patients with myasthenia gravis, azathioprine had the highest discontinuation rate among immunosuppressants due to adverse effects 2.
Infection Risk
In cardiac transplant patients specifically, mycophenolate shows approximately 10% higher rates of opportunistic infections compared to azathioprine, particularly herpes virus infections (H. simplex, H. zoster, and cytomegalovirus) 1. However, this did not translate to excess mortality from infection/sepsis 1.
Hematologic Effects
Both agents can cause bone marrow suppression and should never be administered concomitantly 1. Complete blood counts should be monitored weekly during the first month, twice monthly for months 2-3, then monthly through the first year for mycophenolate 1.
Gender Considerations
Women experience higher frequencies of side effects from both agents, which is particularly relevant given teratogenicity concerns that already limit options in women of reproductive potential 2.
Clinical Implications
The choice between these agents should prioritize:
- Avoid azathioprine in patients with pre-existing liver disease or elevated transaminases
- Avoid mycophenolate in patients with active peptic ulcer disease, inflammatory bowel disease, or those unable to tolerate GI side effects 1
- Consider mycophenolate first-line when tolerability is the primary concern, as discontinuation rates are lower 2
- Monitor liver function tests closely with azathioprine (check at baseline, 2 weeks, then monthly for 3 months, then every 3 months)
- Counsel patients on mycophenolate about GI symptoms and the need for prompt reporting of severe diarrhea or bloody stools
Renal Impairment Caveat
In patients with severe chronic renal impairment (GFR < 25 mL/min/1.73 m²), mycophenolate doses should not exceed 1g twice daily, and patients require careful monitoring due to accumulation of metabolites 1.